2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcomeGenetic drivers of heterogeneity in type 2 diabetes pathophysiology
Suzuki K, Hatzikotoulas K, Southam L, Taylor H, Yin X, Lorenz K, Mandla R, Huerta-Chagoya A, Melloni G, Kanoni S, Rayner N, Bocher O, Arruda A, Sonehara K, Namba S, Lee S, Preuss M, Petty L, Schroeder P, Vanderwerff B, Kals M, Bragg F, Lin K, Guo X, Zhang W, Yao J, Kim Y, Graff M, Takeuchi F, Nano J, Lamri A, Nakatochi M, Moon S, Scott R, Cook J, Lee J, Pan I, Taliun D, Parra E, Chai J, Bielak L, Tabara Y, Hai Y, Thorleifsson G, Grarup N, Sofer T, Wuttke M, Sarnowski C, Gieger C, Nousome D, Trompet S, Kwak S, Long J, Sun M, Tong L, Chen W, Nongmaithem S, Noordam R, Lim V, Tam C, Joo Y, Chen C, Raffield L, Prins B, Nicolas A, Yanek L, Chen G, Brody J, Kabagambe E, An P, Xiang A, Choi H, Cade B, Tan J, Broadaway K, Williamson A, Kamali Z, Cui J, Thangam M, Adair L, Adeyemo A, Aguilar-Salinas C, Ahluwalia T, Anand S, Bertoni A, Bork-Jensen J, Brandslund I, Buchanan T, Burant C, Butterworth A, Canouil M, Chan J, Chang L, Chee M, Chen J, Chen S, Chen Y, Chen Z, Chuang L, Cushman M, Danesh J, Das S, de Silva H, Dedoussis G, Dimitrov L, Doumatey A, Du S, Duan Q, Eckardt K, Emery L, Evans D, Evans M, Fischer K, Floyd J, Ford I, Franco O, Frayling T, Freedman B, Genter P, Gerstein H, Giedraitis V, González-Villalpando C, González-Villalpando M, Gordon-Larsen P, Gross M, Guare L, Hackinger S, Hakaste L, Han S, Hattersley A, Herder C, Horikoshi M, Howard A, Hsueh W, Huang M, Huang W, Hung Y, Hwang M, Hwu C, Ichihara S, Ikram M, Ingelsson M, Islam M, Isono M, Jang H, Jasmine F, Jiang G, Jonas J, Jørgensen T, Kamanu F, Kandeel F, Kasturiratne A, Katsuya T, Kaur V, Kawaguchi T, Keaton J, Kho A, Khor C, Kibriya M, Kim D, Kronenberg F, Kuusisto J, Läll K, Lange L, Lee K, Lee M, Lee N, Leong A, Li L, Li Y, Li-Gao R, Ligthart S, Lindgren C, Linneberg A, Liu C, Liu J, Locke A, Louie T, Luan J, Luk A, Luo X, Lv J, Lynch J, Lyssenko V, Maeda S, Mamakou V, Mansuri S, Matsuda K, Meitinger T, Melander O, Metspalu A, Mo H, Morris A, Moura F, Nadler J, Nalls M, Nayak U, Ntalla I, Okada Y, Orozco L, Patel S, Patil S, Pei P, Pereira M, Peters A, Pirie F, Polikowsky H, Porneala B, Prasad G, Rasmussen-Torvik L, Reiner A, Roden M, Rohde R, Roll K, Sabanayagam C, Sandow K, Sankareswaran A, Sattar N, Schönherr S, Shahriar M, Shen B, Shi J, Shin D, Shojima N, Smith J, So W, Stančáková A, Steinthorsdottir V, Stilp A, Strauch K, Taylor K, Thorand B, Thorsteinsdottir U, Tomlinson B, Tran T, Tsai F, Tuomilehto J, Tusie-Luna T, Udler M, Valladares-Salgado A, van Dam R, van Klinken J, Varma R, Wacher-Rodarte N, Wheeler E, Wickremasinghe A, van Dijk K, Witte D, Yajnik C, Yamamoto K, Yamamoto K, Yoon K, Yu C, Yuan J, Yusuf S, Zawistowski M, Zhang L, Zheng W, Raffel L, Igase M, Ipp E, Redline S, Cho Y, Lind L, Province M, Fornage M, Hanis C, Ingelsson E, Zonderman A, Psaty B, Wang Y, Rotimi C, Becker D, Matsuda F, Liu Y, Yokota M, Kardia S, Peyser P, Pankow J, Engert J, Bonnefond A, Froguel P, Wilson J, Sheu W, Wu J, Hayes M, Ma R, Wong T, Mook-Kanamori D, Tuomi T, Chandak G, Collins F, Bharadwaj D, Paré G, Sale M, Ahsan H, Motala A, Shu X, Park K, Jukema J, Cruz M, Chen Y, Rich S, McKean-Cowdin R, Grallert H, Cheng C, Ghanbari M, Tai E, Dupuis J, Kato N, Laakso M, Köttgen A, Koh W, Bowden D, Palmer C, Kooner J, Kooperberg C, Liu S, North K, Saleheen D, Hansen T, Pedersen O, Wareham N, Lee J, Kim B, Millwood I, Walters R, Stefansson K, Ahlqvist E, Goodarzi M, Mohlke K, Langenberg C, Haiman C, Loos R, Florez J, Rader D, Ritchie M, Zöllner S, Mägi R, Marston N, Ruff C, van Heel D, Finer S, Denny J, Yamauchi T, Kadowaki T, Chambers J, Ng M, Sim X, Below J, Tsao P, Chang K, McCarthy M, Meigs J, Mahajan A, Spracklen C, Mercader J, Boehnke M, Rotter J, Vujkovic M, Voight B, Morris A, Zeggini E. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature 2024, 627: 347-357. PMID: 38374256, PMCID: PMC10937372, DOI: 10.1038/s41586-024-07019-6.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesChromatinCoronary Artery DiseaseDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionEndothelial CellsEnteroendocrine CellsEpigenomicsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansIslets of LangerhansMultifactorial InheritancePeripheral Arterial DiseaseSingle-Cell AnalysisConceptsGenome-wide association study dataIndividuals of diverse ancestryRegions of open chromatinAncestry groupsGenome-wide significanceSingle-cell epigenomicsCases of T2DT2D signalsAssociation signalsObesity-related processesOpen chromatinDiverse ancestryTrait associationsDrivers of heterogeneityGenetic driversProgression of T2DEnteroendocrine cellsType 2 diabetes pathophysiologyGenetic contributionMolecular mechanismsPolygenic scoresAncestryLociPancreatic isletsStudy dataAssessment of valve regurgitation severity via contrastive learning and multi-view video integration
Kim S, Ren H, Charton J, Hu J, Gonzalez C, Khambhati J, Cheng J, DeFrancesco J, Waheed A, Marciniak S, Moura F, Cardoso R, Lima B, McKinney S, Picard M, Li X, Li Q. Assessment of valve regurgitation severity via contrastive learning and multi-view video integration. Physics In Medicine And Biology 2024, 69: 045020. PMID: 38271727, DOI: 10.1088/1361-6560/ad22a4.Peer-Reviewed Original ResearchConceptsRepresentation learningContrastive learningMulti-view video processingState-of-the-art methodsContrastive learning frameworkState-of-the-artIn-house datasetVideo processingContrastive networkEmbedding spaceImage inputLearning frameworkVideo integrationIntricate taskLoss termMulti-modal clinical dataLearningRepresentationLabor-intensiveAccuracyEfficient methodVideo seriesEmbeddingDatasetNetwork
2023
Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure
Souza A, Rosenthal M, Moura F, Divakaran S, Osborne M, Hainer J, Dorbala S, Blankstein R, Di Carli M, Taqueti V. Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure. JACC Cardiovascular Imaging 2023, 17: 179-191. PMID: 37768241, PMCID: PMC10922555, DOI: 10.1016/j.jcmg.2023.07.014.Peer-Reviewed Original ResearchConceptsCoronary microvascular dysfunctionVisceral adipose tissueAssociated with coronary microvascular dysfunctionCoronary flow reserveBody mass indexLow coronary flow reserveSubcutaneous adipose tissueCoronary artery diseaseAdverse eventsPositron emission tomographyObese patientsMicrovascular dysfunctionVisceral adipose tissue cross-sectional areaCardiovascular eventsHeart failurePreserved left ventricular ejection fractionAdverse outcomesSkeletal muscleArtery diseaseFlow-limiting coronary artery diseaseBody compositionAssociated with body compositionEvaluation of coronary artery diseaseStress positron emission tomographyEmission tomographyRisk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian follow-upRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify riskEfficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
de Mesquita Y, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao E, Carvalho P, da Silva C, Cardoso R, Moura F, Rafalskiy V. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal Of Obesity 2023, 47: 883-892. PMID: 37460681, DOI: 10.1038/s41366-023-01337-x.Peer-Reviewed Original ResearchConceptsMean differenceRandomized controlled trialsOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsControlled trialsMeta-analysisCo-primary endpointsMethodsWe searched PubMedType 2 diabetesAgonist tirzepatideRisk of biasReview Manager 5.4.1Receptor agonistsReduced BMITherapeutic optionsWaist circumferenceAdverse eventsTirzepatideGastrointestinal symptomsPooled analysisGLP-1PlaceboWeight managementAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohort
2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomesTirzepatide for diabetes: on track to SURPASS current therapy
Moura F, Scirica B, Ruff C. Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine 2022, 28: 450-451. PMID: 35260841, DOI: 10.1038/s41591-022-01733-2.Peer-Reviewed Original Research
2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2020
Role of myocardial strain imaging in surveillance and management of cancer therapeutics‐related cardiac dysfunction: A systematic review
McGregor P, Moura F, Banchs J, Aragam J. Role of myocardial strain imaging in surveillance and management of cancer therapeutics‐related cardiac dysfunction: A systematic review. Echocardiography 2020, 38: 314-328. PMID: 33277729, DOI: 10.1111/echo.14944.Peer-Reviewed Original ResearchConceptsCancer therapeutics-related cardiac dysfunctionLeft ventricular ejection fractionManagement of Cancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainSpeckle-tracking echocardiographyMyocardial strain imagingCardiac dysfunctionPeak systolic global longitudinal strainLeft ventricular ejection fraction assessmentSystolic global longitudinal strainVentricular ejection fractionCardiac imaging modalitiesAdverse cardiac eventsMyocardial deformation imagingTransthoracic echocardiographyEjection fractionCardiac eventsStrain imagingMyocardial changesCancer patientsMyocardial strainGLS measurementsLongitudinal strainImaging modalitiesPRISMA guidelinesA current review of COVID-19 for the cardiovascular specialist
Lang J, Wang X, Moura F, Siddiqi H, Morrow D, Bohula E. A current review of COVID-19 for the cardiovascular specialist. American Heart Journal 2020, 226: 29-44. PMID: 32497913, PMCID: PMC7252118, DOI: 10.1016/j.ahj.2020.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAlanineAntimalarialsAntiviral AgentsBetacoronavirusBiomarkersCardiovascular DiseasesChloroquineCoronavirus InfectionsCOVID-19HumansHydroxychloroquineHypoxiaPandemicsPlasmaPneumonia, ViralReceptor, Angiotensin, Type 2Risk FactorsSARS-CoV-2Takotsubo CardiomyopathyVirus InternalizationConceptsAcute cardiac injuryCardiac injuryAdverse outcomesLevels of cardiac troponinAssociated with adverse outcomesHyperinflammatory cytokine stormType 2 myocardial infarctionPre-existing cardiovascular diseaseLevel of suspicionComplications of COVID-19Stress-related cardiomyopathyIncreased blood levelsCardiovascular risk factorsNonischemic myocardial injurySevere COVID-19Cardiovascular complications of COVID-19Nonischemic causesTakotsubo syndromeNatriuretic peptideD-dimerHigher mortality riskCardiovascular complicationsDiffuse thrombosisInflammatory milieuMyocardial dysfunction
2019
Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
Sposito A, Carvalho L, Moura F, Campos-Staffico A, Cintra R, Nadruz W, Almeida O, Quinaglia e Silva J. Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Scientific Reports 2019, 9: 16401. PMID: 31704948, PMCID: PMC6841947, DOI: 10.1038/s41598-019-52111-x.Peer-Reviewed Original ResearchConceptsEuglycemic hyperinsulinemic clampMyocardial infarctionInsulin sensitivityAcute phaseShort-course treatmentInfluence glucose homeostasisAssociated with mortalityDose-dependent mannerStable patientsClinical outcomesProspective studyStatinsHyperinsulinemic clampPatientsExperimental modelGlucose homeostasisHOMA2DaysExcess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity
de Lima-Junior J, Virginio V, Moura F, Bertolami A, Bertolami M, Coelho-Filho O, Zanotti I, Nadruz W, de Faria E, de Carvalho L, Sposito A. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition Metabolism And Cardiovascular Diseases 2019, 30: 254-264. PMID: 31753789, DOI: 10.1016/j.numecd.2019.09.017.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessBody mass indexCholesterol efflux capacityReduced cholesterol efflux capacityNon-diabetic individualsNon-obeseHDL-CIncreased values of BMIAtherosclerotic burdenEfflux capacityValues of body mass indexElevation of body mass indexProtective function of HDLIncreased BMIObesity-related declineInhibition of platelet aggregationHigh-density lipoprotein (HDLIncreased atherosclerotic burdenAssociated with carotid intima-media thicknessIncreased HDL-CDecreased HDL concentrationIntima-media thicknessFunction of HDLLipoprotein (HDLPlatelet aggregation inhibitionReciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction
Sposito A, de Lima-Junior J, Moura F, Barreto J, Bonilha I, Santana M, Virginio V, Sun L, Carvalho L, Soares A, Nadruz W, Feinstein S, Nofer J, Zanotti I, Kontush A, Remaley A. Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction. Arteriosclerosis Thrombosis And Vascular Biology 2019, 39: 1550-1564. PMID: 31189429, DOI: 10.1161/atvbaha.119.312880.Peer-Reviewed Original ResearchConceptsMyocardial infarctionHigh-density lipoproteinSphingosine-1-phosphateSpectrum of signaling pathwaysEndothelin-1Cardiac functionCardioprotective benefitsTherapeutic advancesClinical studiesIschemia/reperfusion injuryProinflammatory moleculesAnimal modelsInsulin sensitivityHDLInfarctionMitochondrial channelsFunctional changesOxidative stressSignaling pathwayOmega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction
Campos-Staffico A, Costa A, Carvalho L, Moura F, Santos S, Coelho-Filho O, Nadruz W, Quinaglia e Silva J, Sposito A. Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. Nutrition Journal 2019, 18: 29. PMID: 31060562, PMCID: PMC6503367, DOI: 10.1186/s12937-019-0455-1.Peer-Reviewed Original ResearchConceptsCardiac magnetic resonance imagingAcute inflammatory responseCardiac remodelingInflammatory responseAssociated with attenuated inflammatory responsesLeft ventricle ejection fractionBrain-type natriuretic peptideHs-C-reactive proteinFood frequency questionnaireEnd-diastolic volumeReduced daily intakeLeft ventricular remodelingOmega-3 intakeLeft ventricle end-diastolic volumeOmega-3 polyunsaturated fatty acidsExcessive inflammatory responseAssociated with attenuationAnti-inflammatory effectsMagnetic resonance imagingFrequency questionnaireEjection fractionNatriuretic peptideResultsThe intakeInflammatory markersVentricular remodelingInhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Cintra R, Moura F, Carvalho L, Barreto J, Tambascia M, Pecoits-Filho R, Sposito A. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira 2019, 65: 70-86. PMID: 30758423, DOI: 10.1590/1806-9282.65.1.70.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsRisk of hypoglycemiaAntidiabetic therapySodium-glucose co-transporter 2High risk of hypoglycemiaIncreased risk of hypoglycemiaPrevalence of type 2 diabetes mellitusType 2 diabetes mellitusRenal proximal convoluted tubulesChronic kidney diseaseCo-morbid diseasesSystolic blood pressurePost hoc studyProximal convoluted tubulesReduced insulin sensitivitySGLT2i therapyMedian ageSodium-glucoseSodium reabsorptionOlder individualsClinical trialsIncreased riskKidney diseaseBlood pressureConvoluted tubules
2017
Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction
Moura F, Cintra R, Carvalho L, Santos S, Modolo R, Munhoz D, Quinaglia e Silva J, Coelho O, Nadruz W, Sposito A. Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction. International Journal Of Cardiology 2017, 254: 16-22. PMID: 29246426, DOI: 10.1016/j.ijcard.2017.11.111.Peer-Reviewed Original ResearchConceptsST-elevation MIGRACE risk scoreInsulin sensitivity changesIntra-hospital deathMyocardial infarctionFollow-upMI hospitalizationAssociated with increased mortalityMarkers of glucose metabolismCox regression modelsInsulin provision therapyProspective cohortRisk scoreNet reclassification indexCardiac eventsAdverse cardiac eventsUpstream markersCox regressionAdverse outcomesHomeostasis model assessmentEstimate insulin sensitivityReclassification indexU-shaped relationStress hyperglycemiaInsulin sensitivitySarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly
Campos A, Moura F, Santos S, Freitas W, Sposito A, Study O. Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly. Atherosclerosis 2017, 258: 138-144. PMID: 28129889, DOI: 10.1016/j.atherosclerosis.2017.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdiposityAge FactorsAged, 80 and overAsymptomatic DiseasesBody CompositionCoronary AngiographyCoronary Artery DiseaseCross-Sectional StudiesEndothelium, VascularEnergy IntakeExercise TestExercise ToleranceFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultidetector Computed TomographyMultivariate AnalysisMuscle StrengthMuscle, SkeletalNutrition AssessmentNutritional StatusOdds RatioOverweightProspective StudiesRisk FactorsSarcopeniaVasodilationWeight GainConceptsCoronary heart diseaseAssociated with subclinical atherosclerosisCoronary calcium scoreFlow-mediated dilationExcess weightSubclinical atherosclerosisOdds ratioFatty massMuscle massPhysical performance testsCoronary heart disease riskElderly individualsRisk of coronary heart diseaseAssociated with coronary heart diseaseCaloric intakeIncreased risk of coronary heart diseaseStudy of CohortsEndothelial dysfunctionCross-sectional studySkeletal muscle indexAssociated with flow-mediated dilationGait speedCardiac computed tomographyReduction of muscle massMultivariate regression model
2015
Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction
Modolo R, Figueiredo V, Moura F, Almeida B, Quinaglia e Silva J, Nadruz W, Lemos P, Coelho O, Blaha M, Sposito A. Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction. Coronary Artery Disease 2015, 26: 562-566. PMID: 26010531, DOI: 10.1097/mca.0000000000000269.Peer-Reviewed Original ResearchConceptsCoronary artery calcification scoreST-elevation myocardial infarctionCoronary artery calcificationMyocardial blush gradeTIMI flowAssociated with impaired reperfusionST-elevation myocardial infarction patientsCoronary angiographic severityCardiac computed tomographyConsecutive STEMI patientsTIMI flow ratesNonculprit coronary arteryCoronary thrombus burdenArtery calcification scoreAcute coronary syndromeNo-reflow phenomenonHigher heart rateCoronary blood flowCAC scoreOptimal reperfusionCalcification scoreClinical characteristicsAngiographic severityBlush gradeSTEMI patients